EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1‐inactivated malignant pleural mesothelioma: a multicentre, open‐label, phase 2 study. The gene discussed is BAP1; the disease is malignant pleural mesothelioma.